Premium
Repetitive Immunoadsorption Cycles for Treatment of Severe Atopic Dermatitis
Author(s) -
Daeschlein Georg,
Scholz Sebastian,
Lutze Stine,
Eming Ruediger,
Arnold Andreas,
Haase Hermann,
Hertl Michael,
Jünger Michael
Publication year - 2015
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12267
Subject(s) - medicine , scorad , immunoadsorption , atopic dermatitis , immunoglobulin e , regimen , gastroenterology , dermatology , immunology , antibody , disease , dermatology life quality index
The purpose of the study was to investigate the clinical efficacy of repetitive IgE immunoadsorption ( IA ) cycles in severe atopic dermatitis ( AD ) with high serum IgE levels. A total of seven patients with severe AD with a history of no significant or longterm S coring A topic D ermatitis ( SCORAD ) reduction and total serum IgE levels >700 IU/mL were enrolled. The patients received one to five series of IA ( I g‐ T herasorb adsorber columns; M iltenyi B iotec, T eterow, G ermany) each consisting of five consecutive treatments which were performed on a monthly regimen. Overall, one patient received one, two patients two, one patient three, two patients four and one patient five cycles of IA . IA was well tolerated in all the studied AD patients and led to a significant decrease of SCORAD and IgE levels during each IA cycle in all the patients. The relative decrease of SCORAD and serum IgE levels after treatment was 11.1% and 80%, respectively, after five immunoadsorption series, 24.1% and 83.6%, respectively, after four series, 37.6% and 75.9%, respectively, after three series, 27.9% and 74.2%, respectively, after two series, and 25.1% and 74.8% after the 1st IA cycle. One of the patients exhibited a long lasting clinical benefit over more than 12 months after the 5th IA cycle. Repetitive IA with more than two cycles at intervals of 4 weeks induces a profound and persisting IgE reduction which is remarkable clinical efficacy improving SCORAD in severe AD with high serum IgE levels.